JPMorgan Cazenove has reiterated its 'overweight' rating and 430p target price for insurance group Standard Life, adding the stock to its European 'Analyst Focus List'.The bank pointed out that the stock has been under pressure since the start of the week, partly due to erroneous data implying net outflows of £1bn in the John Hancock Global Absolute Return Strategies (GARS) fund in September. However, data has subsequently been adjusted to include the retail fund and the institutional fund, and now shows net inflows in the fund overall. JPMorgan said that the GARS fund has seen net positive inflows of £1.2bn in the third quarter.GlaxoSmithKline's share price edged higher on Friday morning on hopes that generic versions of its best-selling drug Advair may not come to market until later than expected - something that Panmure Gordon believes is a reason to 'buy' the UK-listed stock.The broker highlighted comments from Teva, the world's largest generic manufacturer, which implied that it did not expect Advair generics until 2018 at the earliest. "This, together with news of significant progress in GSK2606414 in Alzheimer's disease, prompts us to reiterate our 'buy' recommendation and point to today's level as good entry level to the stock," said analyst Savvas Neophytou.Whitbread, the owner of the Premier Inn, Beefeater and Costa chains, was making gains on Friday morning after Citigroup upgraded the stock from 'neutral' to 'buy', saying it is the "best exposed to the expected rapid economic recovery that we think is underway in the UK".Citi expects a "solid" interim report on October 22nd from the group and forecasts earnings before interest and tax of £229m. The target price for the stock has been increased from 2,900p to 3,570p.BC